Fiberoptic Bronchoscopy



Fiberoptic Bronchoscopy


Alexander C. Chen

Daniel J. Brown



General Principles



  • Fiberoptic bronchoscopy (FOB) was developed by Shigeto Ikeda in the 1960s.


  • FOB has become a vital procedure for pulmonologists, with nearly 500,000 procedures performed in the United States every year.1


  • The rise of the field of interventional pulmonology has increased the diagnostic and therapeutic range of the bronchoscope.


  • As technology has improved, indications for FOB have increased (Table 4-1).


  • Most contraindications are relative, and potential reward must merit the possible risk (Table 4-2). The major absolute contraindication is a significant increase in intracranial pressure (ICP), as coughing during the procedure can further increase ICP leading to brain herniation.








TABLE 4-1 INDICATIONS FOR FIBEROPTIC BRONCHOSCOPY















































Inspection of Evaluation, Diagnosis, or Management of   Other
Upper aerodigestive tract, larynx, vocal cords, and related structures Chronic cough Tracheoesophageal fistula Assisting in intubation and extubation
  Wheezing Tumor Assisting percutaneous tracheostomy
  Pneumonia Tracheobronchial stenosis Brachytherapy
The major conductive airways Persistent pulmonary infiltrates Foreign body Intralesional injection of drugs
  Disrupted bronchial tree secondary to trauma Persistent atelectasis Brachytherapy
  Thermal or chemical inhalational injury Lymphadenopathy Stent placement
  Anastomotic sites after lung transplantation Pulmonary nodule Surveillance for rejection after lung transplantation
  Position/patency of an ETT/tracheostomy tube    









TABLE 4-2 RELATIVE CONTRAINDICATIONS TO BRONCHOSCOPY






















Relative Contraindication
Life-threatening arrhythmias
Severe hypoxemia
Recent myocardial infarction
Unstable angina
Uncorrected bleeding diathesis
Severe pulmonary hypertension
Thrombocytopenia
Superior vena cava syndrome
Unstable cervical spine


Prebronchoscopy Evaluation



  • In an American College of Chest Physicians (ACCP) survey, a majority of operators obtain a preprocedure chest radiograph, coagulation studies, and complete blood count. Less than one-half obtain an EKG, arterial blood gas, electrolytes, or pulmonary function tests.2 Routine preprocedure labs are not absolutely indicated unless specific concerns exist.


  • Cardiac evaluation in patients with known coronary disease undergoing elective bronchoscopy can be considered, and guidelines have been published by the American College of Cardiology/American Heart Association.3


Procedural Medications



  • Medications are commonly used before and during bronchoscopy to facilitate a safe, comfortable, and successful procedure.


  • Antisialogogues are used with the intent of drying secretions and reducing the vasovagal response.



    • Atropine 0.4 mg IM is the antisialogogue most commonly used.


    • There are no convincing data that antisialogogues are efficacious, and because of the side effects, they are not recommended on a routine basis.4


  • Benzodiazepines play a central role in providing amnesia and anxiolysis.

Nov 20, 2018 | Posted by in RESPIRATORY | Comments Off on Fiberoptic Bronchoscopy

Full access? Get Clinical Tree

Get Clinical Tree app for offline access